Table 1.

Clinical trials of HLA antibody reduction with belatacept and plasma cell targeting therapies

Carfilzomib and Belatacept for Desensitization (ADAPT)	Desensitization	NCT05017545	Recruiting	Phase 1/2 open-label non-randomized clinical trial to address the safety and efficacy of belatacept and carfilzomib in highly HLA sensitized kidney transplant candidates.
Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization	Desensitization and AMR	NCT03805178	Withdrawn	Phase 2 open-label non-randomized clinical trial to address safety and tolerability in highly sensitized lung transplant candidates and lung transplant recipients with antibody mediated rejection (AMR).
Novel Desensitization Kidney Transplantation	Desensitization	NCT05345717	Recruiting	Open-label pilot study to test the safety and effectiveness of desensitization therapy with belatacept and proteasome inhibitor to increase the likelihood of finding an acceptable donor for highly HLA sensitized kidney transplant candidates.
Daratumumab and Belatacept for Desensitization (ATTAIN)	Desensitization	NCT04827979	Recruiting	Phase 1/2 open-label non-randomized, clinical trial to assess the safety and efficacy of daratumumab and belatacept in highly HLA sensitized kidney transplant candidates.
The Safety/Efficacy Of Daratumumab With Belatacept In Highly HLA-Sensitized Patients Awaiting Kidney Transplantation (COMBAT)	Desensitization	NCT05145296	Recruiting	Non-randomized, single-center pilot trial assessing the safety and efficacy of targeting peripheral and central humoral alloimmune memory with daratumumab and belatacept in highly HLA sensitized patients awaiting kidney transplantation.